



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Date: 09 November 2023**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)**

Dear Sir/Madam,

We would like to inform that the Company has availed a Term Loan Facility from Citi Bank N.A. amounting to Rs. 280,00,00,000/- (Indian Rupees Two Hundred and Eighty Crores) for financing the acquisition of the Nephrology and Dermatology businesses pertaining to the Indian Territory of Biocon Biologics Limited as informed by the Company on November 08, 2023.

In accordance with requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B (5) of Part A of Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, details attached herein shall be taken on record.

Thanking You,

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**Membership No: A26493**  
**Encl: As above**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



**Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course of business, revision(s) or amendment(s) and termination(s) thereof:**

Sr. No.	Particulars	Details
1.	name(s) of parties with whom the agreement is entered	<b>Lender:</b> Citibank, N.A. (“ <b>Bank</b> ”)  <b>Borrower:</b> Eris Lifesciences Limited (“ <b>Company</b> ”)
2.	purpose of entering into the agreement	To avail a term loan facility of INR 280,00,00,000/- (Indian Rupees Two Hundred and Eighty Crores) for financing the acquisition of the Nephrology and Dermatology businesses pertaining to the Indian Territory of Biocon Biologics Limited as informed by the Company on November 08, 2023.
3.	size of agreement	₹ 280,00,00,000/- (Indian Rupees Two Hundred and Eighty Crores)
4.	shareholding, if any, in the entity with whom the agreement is executed	NIL
5.	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	The terms of the term loan agreement includes inter alia, the following actions:  All restrictions/ covenants (positive/negative)/ customary terms and conditions as generally applicable for borrowing of funds of similar type and scale.
6.	whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	NA
7.	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	NA
8.	in case of issuance of shares to the parties, details of issue price, class of shares issued	NA
9.	in case of loan agreements:  ➤ details of lender/borrower,  ➤ nature of the loan,  ➤ total amount of loan granted/taken,  ➤ total amount outstanding,	Citibank, N.A.  Rupee Term Loan  ₹ 280,00,00,000/- (Indian Rupees Two Hundred and Eighty Crores)  NIL

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



	<ul style="list-style-type: none"> <li>➤ date of execution of the loan agreement/sanction letter</li> <li>➤ details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;</li> </ul>	<p>The loan agreement was executed on November 08, 2023.</p> <p>Exclusive charge on assets acquired through the slump sale transaction including hypothecation charge on brand portfolio acquired from Biocon Biologics Limited.</p>
10.	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	NA
11.	<p>in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):</p> <ul style="list-style-type: none"> <li>i. name of parties to the agreement;</li> <li>ii. nature of the agreement;</li> <li>iii. date of execution of the agreement;</li> <li>iv. details of amendment and impact thereof or reasons of termination and impact thereof.</li> </ul>	NA

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867